Key facts
- It has raised $3.3M across 2 recorded rounds; the latest was Seed Round ($250K) in Apr 2022.
- Notable investors include National Cancer Institute, U.S. Department of Health and Human Services.
- UbiVac has filed 8 Form Ds with the SEC since 2017, most recently Mar 2025 ($35K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for UbiVac
Funding rounds
2 roundsAbout UbiVac
Operator of a biotech company intended to develop therapeutic immune activators and vaccines to combat cancer. The company offers a patented vaccine technology, utilizing non-mutated shared cancer neoantigens, enabling cancer patients to experience enhanced immune responses, offering the potential for increased survival and cure.
- Sector
- Healthcare
- HQ
- Portland, OR, United States
- Founded
- 2005
- Employees
- 14
- Website
- ubivac.com/
- Ownership
- Privately Held (backing)
UbiVac doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in UbiVac shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on UbiVac in its N-PORT filings yet. We sweep new filings monthly.